Then, early last month, President Donald Trump announced expansive new tariffs on much of the world. Adjustments and carve-outs followed. But from March 31 to April 30, the report said, Wall Street ...

The short interest in Hims & Hers Health (NYSE:HIMS) has approached critical levels, financial data provider S3 Partners said ...

We recently published a list of What Propelled These 10 Firms’ Double-Digit Gains? In this article, we are going to take a ...

The stock market ended the trading week on a strong note, with all major indices clocking in strong gains, as investors cheered better-than-expected non-farm payrolls last month while digesting more ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

We recently published a list of 10 Firms Lead Rally on Impressive Q1 Earnings, Optimistic Outlooks. In this article, we are ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

Wegovy, the popular weight-loss drug from Novo Nordisk, will be available through several leading telehealth providers, ...